PCSK9 inhibitors in the management of cardiovascular risk: A practical guidance

Document Type

Review Article

Department

Office of the Provost; Cardiology

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.

Comments

Issue No are not provided by the author/publisher. This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Vascular health and risk management

Link to Full Text

Share

COinS